Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in […]
Oxford, UK, 05 January 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range […]
Dr Jordan Palfry will be attending TIDES Europe between the 16th and 18th November. If you have an interest in peptide discovery, be it for targeting cells, PROTACS and molecular Glues or for functional screening in identifying GPCR agonists, please connect via info@orbitdiscovery.com. We look forward to meeting you in Boulder
Project will use microfluidic technology to improve efficiency of peptide therapeutics discovery for challenging drug target Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the […]
Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi […]
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, […]
Oxford, United Kingdom, June 29, 2021: Orbit Discovery Ltd (“Orbit”), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer. With an extensive track record in commercialising proprietary drug discovery platforms, Dr Butt joins Orbit to oversee the Company’s […]
Oxford, UK: 30th August 2019 Orbit Discovery, an Oxford, UK-based biotech company developing an industry-leading peptide discovery platform, are pleased to announce that Dr Mario Polywka has joined their board as a non-executive director. Mario Polywka brings exceptional operational, commercial and strategic development experience to Orbit Discovery. He retired as Chief Operating Officer of Evotec […]